JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

NewsGuard 100/100 Score

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD). The comprehensive study, which examined 1,715 NMSC lesions in 1,149 patients, dubbed "Superficial x-ray in the treatment of basal and squamous cell carcinomas", was authored by Dr. Armand Cognetta and his colleagues. The study finds that SRT is a viable and effective modality in the physician's toolbox to successfully treat NMSC patients with high cure rates and is complimentary to surgery and other treatment methods.

"The acceptance and publication of this study by the AAD society is very important and timely, considering the contemporary clinical and economic landscape, where there is an ongoing endeavor to employ sound and cost-effective methods to treat patients non-invasively, which will essentially lower the burden on the healthcare system and the economy in general, while maximizing clinical outcomes, cure rates, and overall patient quality of life. The SRT-100™ is in the sweet spot of addressing the challenges our society is coping with nowadays, while offering the patients and physicians excellent results. We are proud to be on the forefront of providing a treatment solution that is truly beneficial to everyone involved in this equation – the patients, physicians, and the healthcare system," stated Joe Sardano, President/CEO, Sensus Healthcare.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer